Navigation Links
Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
Date:9/14/2010

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced the presentation of new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.  During an oral presentation, investigator Oliver Cornely, M.D., of the University of Cologne, presented data showing that fidaxomicin was superior to vancomycin in treating a CDI recurrence and in reducing the chance of another relapse.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

CDI recurrence occurs in approximately 25% of patients treated with existing therapies and there is no agreement in the medical community on the optimal treatment for a recurrence.  In the two fidaxomicin Phase 3 trials, a separate stratum was constructed of subjects who had experienced a prior CDI episode and recurred within three months of entering the study.  The 178 subjects with recurrent CDI  were randomized to be treated with either fidaxomicin or vancomycin and 128 of these subjects were subsequently evaluable for recurrence within the study. Following treatment, 35.5% (22/62) of the subjects who received vancomycin experienced another recurrence compared to 19.7% (13/66) among the subjects who received fidaxomicin (p=.045).  This equates to a 45% reduction in repeat CDI recurrence with fidaxomicin.

"The Phase 3 trials previously showed that fidaxomicin is superior to vancomycin in the prevention of recurrence.  The data presented today show that fidaxomicin is
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
8. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
9. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Cambridge Semantics ... last week’s “Data Demonstration Day” on Capitol Hill, hosted by ... EMC, Google, Microsoft and others to showcase how innovative data ... Accountability and Transparency Act (DATA Act). , Originally introduced in ... (R-CA) and Sen. Mark Warner (D-VA ), ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 The ... Annual Disruptive Innovations to Advance Clinical Trials conference taking ... Hotel in Boston, MA. , Disruptive thinkers from ... and more share bold approaches to reduce expensive infrastructure, ... “Disruptive innovation needs to be big, or novel, or ...
(Date:5/22/2013)... 2013   Oligomerix, Inc. , a privately ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... B financing, which includes both issuance of new ... approximately $2.8M in new investments in the Company.  ... raise. Funding from the Series ...
(Date:5/22/2013)... 2013  Empire Genomics announced today it has ... novel genomic biomarker from Cornell University for use ... help in diagnosing and determining treatment for patients ... Neuroendocrine prostate cancer (NEPC) is a lethal variant ... novo, but more commonly arises after hormonal therapy ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2
... Wisconsin businesses and individuals are invited ... Awards Competition, which recognizes benefits coming from research ... , ,Governor's New Products Awards are given ... more employees); large companies (500-999 employees); medium companies ...
... 2003, I wrote on an article on "The Final Death ... was on the walls of the demise of Searle due ... remaining Searle facilities in Chicago. Since then, the Searle name ... to another article I wrote on May 16, 2005, titled ...
... about $400,000 worth of software to Lad Lake ... their families. Rob Busch, enterprise sales manager for Microsoft ... non-profit's Synergy School in Milwaukee for the formal announcement. ... Lad Lakes network and software infrastructure, including the computers ...
Cached Biology Technology:Searle spirit lives on in Chicago as alumni celebrate at former home 2Searle spirit lives on in Chicago as alumni celebrate at former home 3Searle spirit lives on in Chicago as alumni celebrate at former home 4Searle spirit lives on in Chicago as alumni celebrate at former home 5
(Date:5/22/2013)... The feared Legionella pneumophila bacteria is responsible ... pneumonia. In order to infect us, this pathogen has ... and go unnoticed in our cells, thus avoiding these ... the Basque biosciences research centre, CIC bioGUNE, in which ... the USA and the National Supercomputation Centre in Barcelona ...
(Date:5/22/2013)... how climate change will affect interactions between species in ... of Animal Ecology . This knowledge, they say, is ... how species are likely to be impacted by rising ... among biologists that climate change is affecting how species ... to have very important consequences for the stability and ...
(Date:5/22/2013)... Calif., May 22, 2013 Early screening for prostate ... pregnancy testing is for women, thanks to UC Irvine ... American Chemical Society . , After more than a ... way to clearly identify clinically usable markers for prostate ... detected far sooner, with greater accuracy and at dramatically ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... of white blood cell types may help physicians ... and bacterial tonsillitis, potentially guiding treatment decisions, according ... Archives of Otolaryngology–Head & Neck Surgery, one of ... the tonsils) and infectious mononucleosis (caused by the ...
... has found evidence of the Earth's earliest forest trees, dating ... were uncovered after a flash flood in Gilboa, upstate New ... has known what the entire trees looked like. , ... trees which had fallen sideways, with their trunk, branches, twigs ...
... the University of Pennsylvania School of Medicine have discovered ... down a protein that is defective in cystic fibrosis ... from lung cells to airways causes thick mucus to ... therapeutic target for treating lung infections in some cystic ...
Cached Biology News:Common blood test can help distinguish between mononucleosis and tonsillitis 2Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment 2
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
PP2B-Abeta (C-20)...
Goat polyclonal to Duffy / FY / DARC...
... Source: Tritirachium album Description: ... endopeptidase used in a wide range of applications ... peptide bonds mainly following the carboxyl group of ... and is classified as a serine protease. ...
Biology Products: